cine program is implemented, the annualized present value of the cost per QALY gained is -$45,000.
Demmler GJ. Acquired Cytomegalovirus Infections. In: Textbook of Pediatric Infectious Diseases. RD Feigin and JD Cherry eds. Philadelphia, PA: WB Saunder Company, 1992, pp. 1532–1547.
Demmler GJ. Congenital Cytomegalovirus Infection. Seminars in Pediatric Neurology 1994; 1:36–42.
Demmler GJ. Summary of a Workshop on Surveillance for Congenital Cytomegalovirus Disease. Reviews of Infectious Diseases 1991; 13:315–29.
Demmler GJ. Vaccines for Cytomegalovirus. Seminars in Pediatric Infectious Diseases 1991; 2:186–190.
Ho M. Cytomegalovirus. In: Principles and Practice of Infectious Diseases. GL Mandell, JE Bennett, Dolin R eds. New York, NY: Churchill Livingstone, 1995, pp. 1351– 1363.
Institute of Medicine. New Vaccines Development: Establishing Priorities, Volume 1. Diseases of Importance in the United States. Washington, DC: National Academy Press, 1985a.
Istas AS, Demmler GJ, Dobbins JG, et al. Surveillance for Congenital Cytomegalovirus Disease: A Report from the National Congenital Cytomegalovirus Disease Registry. Clinical Infectious Diseases 1995; 20:665–70.
Pass RF. Immunization Strategy for Prevention of Congenital CMV Infection. Infectious Agents and Disease 1996; 5:240–4.
Porath A, McNutt RA, Smiley LM, et al. Effectiveness and Cost Benefit of a Proposed Live Cytomegalovirus Vaccine in the Prevention of Congenital Disease. Reviews of Infectious Diseases 1990; 12:31–40.
Starr SE. Cytomegalovirus Vaccines: Current Status. Infectious Agents and Disease 1992; 1:146–148.
U.S. Bureau of the Census. Statistical Abstract of the U.S.: 1995 (115th edition). Washington, DC, 1995.
Ventura SJ, Martin JA, Mathews TJ, et al. Advance Report of Final Natality statistics, 1994. Monthly Vital Statistics Report 1996; 44.
Yow MD, Demmler GJ. Congenital Megalovirus Disease—20 Years is Long Enough. New England Journal of Medicine 1992; 326:702–703.